Murine pancreatic cancer cells saw the functional modification of exosomes that carry a specific siRNA for targeting oncogenic KRAS, explaining the potential of these exosomes for treating the malignant tumors with identified molecular targets (Xie et al., 2020). Here, KRAS is linked to familial pancreatic carcinoma.